JXN
Price
$140.89
Change
+$3.25 (+2.36%)
Updated
Nov 3, 04:59 PM (EDT)
Capitalization
9.32B
Earnings call today
Intraday BUY SELL Signals
MET
Price
$100.67
Change
-$0.27 (-0.27%)
Updated
Nov 3, 04:59 PM (EDT)
Capitalization
64.15B
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JXN vs MET

JXN vs MET Comparison Chart in %
View a ticker or compare two or three
A.I.Advisor
Nov 02, 2026

Which Stock Would AI Choose? Jackson Financial (JXN) vs. MetLife (MET) Stock Comparison

Key Takeaways

  • JXN (Jackson Financial) is a U.S.-focused retirement and annuity specialist, while MET (MetLife) is a diversified global life insurer with exposure across group benefits, retirement, and international markets.
  • JXN has displayed stronger relative momentum over the trailing twelve months, supported by rising annuity sales and active share repurchases, while MET offers broader diversification and steadier, lower-beta earnings.
  • Both stocks carry "Buy" consensus ratings from analysts, but JXN screens as more volatile with a higher beta, whereas MET offers a larger, more geographically balanced revenue base.
  • Tickeron AI Verdict: JXN is the favored ticker of the two, based on stronger trend consistency, earnings momentum, and nearer-term catalysts.
  • For deeper context, explore JXN Major News and JXN Today's Price Move, as well as MET Major News and MET Today's Price Move.
  • To see how automated strategies are positioning across the market, explore Trending AI Robots.

Introduction

Investors evaluating the insurance and retirement-services sector often weigh a focused, high-growth specialist against a diversified global franchise. That is precisely the contrast between JXN (Jackson Financial) and MET (MetLife). This stock comparison is relevant for traders seeking momentum and catalysts, as well as longer-horizon investors weighing diversification and stability. By examining business models, recent performance, growth drivers, and market positioning, this analysis clarifies how these two names stack up in the current market environment and which one the data currently favors.

JXN Overview and Recent Performance

JXN, or Jackson Financial, is a U.S. retirement-services provider best known for its variable and registered index-linked annuities (RILA), which are annuity products whose returns are tied to an underlying index with defined downside protection. The company has benefited in recent weeks from robust retail annuity sales and continued demand for retirement-income products. Over the trailing twelve months, JXN has delivered a gain of roughly 38%, and its year-to-date performance has been comparably strong, reflecting upward momentum in the shares. Its beta of about 1.3 indicates higher volatility than the broader market. Aggressive share repurchases and a competitive dividend yield have further supported sentiment, while its more concentrated business model leaves it more sensitive to equity-market and interest-rate fluctuations than a diversified peer.

MET Overview and Recent Performance

MET, or MetLife, is one of the world's largest life insurers, with segments spanning Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Investment Management (MIM). In its most recent quarter, MET reported adjusted earnings per share (EPS) growth of roughly 23% year over year, supported by higher net investment income and solid volume growth across segments. Over the past year, the stock has advanced around 24%, with strong contributions from its Group Benefits business. A recently announced multi-billion-dollar buyback authorization and the company's "New Frontier" efficiency program have reinforced the story. Its diversified footprint and steadier earnings profile make it a more defensive holding within financials.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a broader library of hundreds of AI trading bots that collectively monitor thousands of tickers. Each bot operates with its own trading style, timeframe, strategy, risk parameters, and performance track record, so only the strategies best suited to prevailing market conditions earn a place in this featured section. Traders can review statistics, historical performance, and the specific sets of tickers each bot trades. For investors seeking a systematic, data-driven complement to manual analysis, exploring Trending AI Robots offers a practical starting point.

Head-to-Head Comparison

The two companies differ fundamentally in scope. JXN is a concentrated U.S. annuity specialist with a smaller market capitalization, higher beta, and greater sensitivity to equity markets and interest rates. Its growth is driven by product innovation in index-linked annuities and capital returns. MET, by contrast, is a large-cap, globally diversified insurer with multiple earnings streams and a steadier, lower-beta profile. In terms of recent momentum, JXN has outpaced MET on a trailing twelve-month basis, reflecting its more aggressive growth and buyback activity. On valuation, JXN trades at a notably lower forward price-to-earnings (P/E) multiple, while MET commands a higher multiple consistent with its diversification and scale. Risk profiles diverge as well: JXN carries concentration and market-sensitivity risk, while MET faces currency, underwriting, and expense pressures across geographies.

Tickeron AI Verdict

Based on observable factors including trend consistency, earnings momentum, catalyst proximity, and relative positioning, Tickeron's AI currently leans toward JXN as the more compelling of the two tickers. The stock's stronger trailing momentum, higher rate of earnings-per-share growth, aggressive capital-return program, and concentrated exposure to a favorable retirement-income trend support a probabilistic edge in the near-to-intermediate term. That said, MET remains the more stable and diversified alternative, which may appeal to investors prioritizing lower volatility over momentum. This assessment reflects a data-driven comparison rather than a guarantee of future performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
JXN vs. MET commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JXN is a Hold and MET is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for JXN with price predictions
Nov 02, 2026

JXN in upward trend: 10-day moving average crossed above 50-day moving average on November 02, 2026

The 10-day moving average for JXN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JXN as a result. In 62 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for JXN just turned positive on October 22, 2026. Looking at past instances where JXN's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.

JXN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where JXN advanced for three days, in 293 of 379 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 203 of 275 cases where JXN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JXN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

JXN broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. JXN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.989) is normal, around the industry mean (1.339). JXN's P/E Ratio (149.609) is considerably higher than the industry average of (19.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.463). Dividend Yield (0.026) settles around the average of (0.047) among similar stocks. P/S Ratio (1.511) is also within normal values, averaging (1.303).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for MET with price predictions
Nov 02, 2026

MET sees MACD Histogram just turned negative

MET saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 27, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 32 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 60%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for MET moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 25 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 68 cases where MET's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

MET broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on MET as a result. In 47 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

MET moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MET crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +2.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MET advanced for three days, in 224 of 344 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

The Aroon Indicator entered an Uptrend today. In 153 of 283 cases where MET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. MET’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MET's P/B Ratio (2.338) is slightly higher than the industry average of (1.339). P/E Ratio (19.190) is within average values for comparable stocks, (19.974). Projected Growth (PEG Ratio) (0.506) is also within normal values, averaging (0.463). Dividend Yield (0.023) settles around the average of (0.047) among similar stocks. P/S Ratio (0.824) is also within normal values, averaging (1.303).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
MET: Fundamental Ratings
MET
OUTLOOK RATING
1..100
91
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
PROFIT vs RISK RATING
1..100
21
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
28
P/E GROWTH RATING
1..100
12
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JXNMET
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
57%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
56%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
54%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 13 days ago
65%
Declines
ODDS (%)
Bearish Trend 16 days ago
63%
Bearish Trend 7 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
54%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (JXN: $137.64 vs. MET: $100.94)
Brand notoriety: JXN: Not notable vs. MET: Notable
Both companies represent the Life/Health Insurance industry
Current volume relative to the 65-day Moving Average: JXN: 72% vs. MET: 91%
Market capitalization -- JXN: $9.32B vs. MET: $64.15B
JXN [@Life/Health Insurance] is valued at $9.32B. MET’s [@Life/Health Insurance] market capitalization is $64.15B. The market cap for tickers in the [@Life/Health Insurance] industry ranges from $228.36K to $140.68B. The average market capitalization across the [@Life/Health Insurance] industry is $18.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JXN’s FA Score shows that 1 FA rating(s) are green while MET’s FA Score has 3 green FA rating(s).

  • JXN’s FA Score: 1 green, 4 red.
  • MET’s FA Score: 3 green, 2 red.
According to our system of comparison, MET is a better buy in the long-term than JXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JXN’s TA Score shows that 6 TA indicator(s) are bullish while MET’s TA Score has 5 bullish TA indicator(s).

  • JXN’s TA Score: 6 bullish, 3 bearish.
  • MET’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, JXN is a better buy in the short-term than MET.

Price Growth

JXN (@Life/Health Insurance) experienced а +3.77% price change this week, while MET (@Life/Health Insurance) price change was +0.90% for the same time period.

The average weekly price growth across all stocks in the @Life/Health Insurance industry was +1.16%. For the same industry, the average monthly price growth was -0.20%, and the average quarterly price growth was -2.97%.

Reported Earning Dates

JXN is expected to report earnings on Nov 03, 2026.

MET is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Life/Health Insurance (+1.16% weekly)

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

View a ticker or compare two or three
JXN
Daily Signal:
Gain/Loss:
MET
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

JXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, JXN has been loosely correlated with LNC. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if JXN jumps, then LNC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JXN
1D Price
Change %
JXN100%
+2.19%
LNC - JXN
62%
Loosely correlated
+1.44%
CNO - JXN
61%
Loosely correlated
-1.88%
MET - JXN
56%
Loosely correlated
+0.32%
FG - JXN
50%
Loosely correlated
-0.92%
PRU - JXN
50%
Loosely correlated
+0.43%
More

MET and

Correlation & Price change

A.I.dvisor indicates that over the last year, MET has been closely correlated with PRU. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if MET jumps, then PRU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MET
1D Price
Change %
MET100%
+0.32%
PRU - MET
72%
Closely correlated
+0.43%
LNC - MET
69%
Closely correlated
+1.44%
CNO - MET
66%
Closely correlated
-1.88%
PRI - MET
60%
Loosely correlated
-1.16%
JXN - MET
56%
Loosely correlated
+2.19%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NMTC0.980.05
+4.84%
NeuroOne Medical Technologies Corporation
RNA8.720.17
+1.99%
Atrium Therapeutics Inc.
ENTG152.761.20
+0.79%
Entegris
IRT14.81-0.13
-0.87%
Independence Realty Trust
BFS28.67-0.53
-1.82%
Saul Centers